Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZW191 in advanced solid tumors
NCT06555744Phase 1Active, not recruiting
- Sponsor
- Zymeworks Inc.
- Start
- Oct 2024
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 6
01
Overview
Phase 1, open-label, single-arm trial of ZW191 in solid tumor, sponsored by Zymeworks Inc. Primary endpoints: Dose-Limiting Toxicities at 3 weeks, Adverse Events at 2 years and 2 more. Started Oct 2024; status: active, not recruiting.
02
Drugs
ZW191
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06555744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06555744.